The global chronic pain market continues to expand at a steady clip as healthcare systems worldwide confront the dual pressures of an aging population and rising rates of musculoskeletal and neuropathic conditions. Newly released research values the market at USD 77.79 billion in 2023, with growth projected to carry it from USD 81.41 billion in 2024 to USD 117.37 billion by 2031, reflecting a compound annual growth rate of 5.36% over the forecast period. The trajectory highlights sustained investment in pharmaceuticals, medical devices, and digital pain-management platforms designed to improve patient outcomes.

Chronic pain — persistent discomfort lasting three months or longer, often linked to arthritis, back pain, or neuropathy — remains one of the most pervasive and costly public health challenges globally. Data from the U.S. Centers for Disease Control and Prevention indicates that roughly 20.9% of American adults, or 51.6 million people, experienced chronic pain in 2021, with 6.9% suffering from high-impact chronic pain severe enough to restrict daily activity. Prevalence was notably elevated among non-Hispanic American Indian and Alaska Native adults, bisexual individuals, and those who were divorced or separated, underscoring the condition’s uneven social burden.

Innovation Pipeline Fuels Market Confidence

Robust funding activity and clinical progress are reinforcing the market’s growth narrative. Brixton Biosciences recently raised USD 33 million to advance its Neural Ice pain-management platform, while Novartis reported Phase III data confirming the sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria. Such developments illustrate how a combination of venture capital appetite and regulatory momentum is accelerating the translation of novel pain therapeutics from the lab to the clinic.

An aging global population remains the foundational demand driver. As more individuals develop arthritis, chronic back pain, and neuropathy, demand for both pharmacological and non-pharmacological interventions continues to climb, prompting manufacturers to diversify their therapeutic portfolios across drug classes and device categories alike.

No Single Cure Sustains a Complex, Multi-Modal Market

Because chronic pain has no singular cure, the industry is defined by a persistent search for comprehensive, sustainable management solutions that address root causes rather than symptoms alone. This ongoing challenge is spurring continuous innovation across pharmaceuticals, medical devices, and integrative therapeutic approaches. Companies are increasingly turning to personalized medicine strategies — leveraging genetic testing and biomarker identification — to tailor treatment regimens to individual patient profiles, while digital health tools such as telemedicine platforms and wearable monitors are expanding the reach of remote, continuous care.

Minimally Invasive Procedures and Digital Tools Define the Trend Landscape

Technological convergence is reshaping how chronic pain is treated. Minimally invasive surgical procedures are shortening recovery times and improving outcomes, while neuromodulation devices deliver non-pharmacological relief through precise nerve stimulation. Digital pain-management tools are enabling remote monitoring, personalized treatment planning, and richer patient engagement — collectively optimizing care delivery across the treatment continuum.

Pharmaceutical innovation is following a similar globalized trajectory. In December 2023, Forever Cheer, a pharmaceutical company holding more than ten global patents, selected Hong Kong as the launch gateway for its pain-management drug portfolio, aiming to expand its international footprint and broaden access to novel therapies. Rising public awareness of treatment options is also fueling demand, encouraging earlier diagnosis and more proactive healthcare-seeking behavior among patients.

Segment Insights: Drugs Lead, Oncology Set to Surge

By product, drugs represented the largest share of the market in 2023, generating USD 67.53 billion in revenue, driven by rising rates of arthritis and lower back pain and the continuous introduction of new analgesics, opioids, NSAIDs, and topical treatments. Multimodal approaches that blend pharmacological and non-pharmacological therapies are further strengthening this segment’s position.

By indication, chronic back pain held the largest share at 21.87% in 2023, reflecting its global prevalence and the growing sophistication of diagnostic imaging and minimally invasive treatment options. Looking ahead, the oncology application segment is expected to generate the highest revenue by 2031, reaching USD 59.16 billion, as cancer treatment protocols increasingly incorporate specialized pain-management regimens combining opioid analgesics, adjuvant medications, and psychosocial support.

North America Leads, Asia-Pacific Set for Fastest Growth

North America commanded the largest regional share in 2023 at 35.29%, valued at USD 27.45 billion, underpinned by advanced healthcare infrastructure, specialized pain clinics, and supportive reimbursement policies that facilitate access to comprehensive pain care. The region’s emphasis on innovation and chronic disease management continues to position it at the forefront of treatment advancement.

Asia-Pacific, meanwhile, is projected to register the fastest regional growth at a CAGR of 7.26% through 2031, with market value expected to reach USD 29.48 billion. This expansion is propelled by demographic shifts toward an aging population prone to arthritis, improving healthcare infrastructure, and rising adoption of both Western and traditional medicine approaches — a blend that offers patients a broader spectrum of treatment options as regional healthcare expenditure continues to climb.

Competitive Landscape and Strategic Collaboration

The chronic pain market remains fragmented, with leading players pursuing partnerships, mergers and acquisitions, and continuous product innovation to expand their footprints. Companies named in the research include Eli Lilly and Company, Becton, Dickinson and Company, Medtronic plc, Johnson & Johnson, Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Sanofi, and Pfizer Inc.

Illustrating the collaborative trend shaping the industry, digital health innovators MOBE and Override partnered in August 2023 to launch a shared savings program for chronic pain management, combining data analytics and behavioral health coaching to personalize treatment while reducing overall healthcare costs.

Outlook

As global healthcare systems continue to prioritize personalized, technology-enabled pain management, the chronic pain market is set for durable expansion through 2031. Continued investment in neuromodulation, digital therapeutics, and precision medicine is expected to reshape treatment paradigms, offering patients more effective, less invasive options while creating substantial commercial opportunity for pharmaceutical and medical device manufacturers alike.